BACKGROUND Levels of atherogenic lipoproteins achieved with statin therapy are highly variable, but the
T
here is a wealth of evidence that high-dose statin therapy reduces both levels of atherogenic lipoproteins and cardiovascular disease (CVD) risk beyond that achieved with usual-dose statin therapy (1) . However, the evidence on the efficacy of statin therapy is interpreted on the basis of mean reductions of low-density lipoprotein cholesterol (LDL-C) and mean reductions of CVD risk within randomized trials.
There is large interindividual variation in the extent of reduction of atherogenic lipoprotein levels achieved with statin therapy.
Post-hoc analyses of randomized trials suggest that the benefits of statin therapy depend on the extent of achieved LDL-C reduction (2, 3) . In addition, patients achieving very low LDL-C levels have been shown to be at very low CVD risk, although the number of patients achieving such very low levels in any given single trial is usually small (4-6).
The guideline-recommended marker of atherogenic lipoproteins is LDL-C, but we have recently shown that among patients treated with statin therapy, non-highdensity lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (apoB) are at least as strongly associated with CVD risk (7) . Current guidelines consider the target LDL-C level to be in the range of 70 to 130 mg/dl, but observational evidence suggests that this range might be too conservative. Interestingly, novel lipid-lowering therapies, including mipomersen and inhibitors of proprotein convertase subtilisin/kexin 9 (PCSK9), may allow the majority of patients to reach LDL-C levels <70 mg/dl (8) (9) (10) .
However, it is unclear whether pharmacological interventions resulting in atherogenic lipoprotein levels in this anticipated treatment range are beneficial in terms of CVD risk.
It was therefore our objective with this study to assess: 1) the variability of LDL-C, non-HDL-C, and apoB reduction achieved with established statin therapy; 2) the proportion of patients not reaching guideline-recommended LDL-C, non-HDL-C, or apoB levels despite being treated with high-dose statin therapy; and 3) the association between achieved very low LDL-C, non-HDL-C, or apoB levels and the risk for major cardiovascular events.
METHODS
STUDY ELIGIBILITY AND DATA COLLECTION. The methods of this meta-analysis have been described previously (7) . The published reports were searched to identify all randomized controlled trials that assigned study participants in at least 1 of the study groups to statin therapy, and that measured total cholesterol, LDL-C, high-density lipoprotein cholesterol (HDL-C), triglycerides, and apolipoproteins at baseline and during statin therapy in the entire study population. Trials with a mean follow-up for cardiovascular events <2 years and those including <1,000 participants were excluded. The search of published reports was undertaken in PubMed using the following search terms: statin, hydroxymethylglutaryl coenzyme A reductase inhibitor, simvastatin, lovastatin, fluvastatin, pravastatin, atorvastatin, rosuvastatin, cholesterol, apolipoprotein, coronary heart disease, coronary artery disease, and CVD. Investigators were contacted and asked to provide individual patient data. The requested patient characteristics included sex; age; smoking status; body mass index; diabetes mellitus status; systolic and diastolic blood pressure; fasting glucose, total cholesterol, LDL-C, HDL-C, triglycerides, and apo A-I and B concentrations at baseline and at 1-year followup; study medications; and patients' histories of stable coronary heart disease (CHD), myocardial infarction (MI), percutaneous coronary intervention, and coronary artery bypass grafting. The following outcomes (and times to events) were also collected: fatal and nonfatal MI, fatal "other CHD," hospitalization for unstable angina, fatal and nonfatal stroke, fatal and nonfatal hemorrhagic stroke, peripheral artery disease, and congestive heart failure.
Data were harmonized into a pooled database that was independently validated against the original files. The Delphi score assessed the quality of the included trials (11) . This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and a checklist was provided at the time of manuscript submission (12) .
LIPIDS, APOLIPOPROTEINS, STATINS, AND OUTCOME DEFINITIONS. Lipid and apo levels at baseline and at 1-year follow-up were obtained from the participating trials. For on-statin measurements, the 1-year time point was chosen because it was the first uniform time point when apolipoproteins were measured in all participating trials. Cholesterol levels reported in mmol/l were converted to mg/dl by multiplying by 38.7, and triglycerides levels reported in mmol/l were converted to mg/dl by multiplying by 88.5. High-dose statin therapy was defined as either atorvastatin 80 mg or rosuvastatin 20 mg. Usual-dose statin therapy was defined as all other statin dosing regimens.
The primary outcome of this meta-analysis was time to first major cardiovascular event, defined as fatal or nonfatal MI, fatal "other CHD," hospitalization for unstable angina, or fatal or nonfatal stroke. Subanalyses were performed for the prediction of time to first major coronary event (fatal or nonfatal MI, fatal "other CHD," and hospitalization for unstable angina) and time to first major cerebrovascular event (fatal or nonfatal stroke). HDL-C, and apoB levels, using the highest category as reference. LDL-C category cut-offs were chosen as follows: 50, 75, 100, 125, 150, and 175 mg/dl. We also specifically tested whether the risk for major cardiovascular events was lower among patients achieving very low LDL-C levels (<50 mg/dl) compared with those achieving moderately low levels (75 to <100 mg/dl). Equivalent analyses using LDL-C cutoffs <50, <70, <100, <130, <160, and <190 mg/dl, as well as using non-HDL-C cutoffs 30 mg/dl higher, also were performed. Analyses were adjusted for sex, age, smoking status, diabetes mellitus status, systolic blood pressure, HDL-C, and trial. Analyses were not additionally adjusted for prevalent CHD because all trials enrolled either 0% or 100% patients with prevalent disease, so adjustment for trial implies adjustment for prevalent CHD. However, prevalent CHD as an inclusion criterion was documented less rigorously in some trials than in other trials.
Separate analyses for the outcomes of major cardiovascular events, major coronary events, major cerebrovascular events, and hemorrhagic stroke were n ¼ 7,783) (Fig. 1B) , a dose increase from usual-dose to high-dose statin (patients with atorvastatin dose increased from 10 to 80 mg in the TNT [Treating to
New Targets] trial [5] ; n ¼ 4,636) (Fig. 1C) , and patients not treated with statin therapy (patients enrolled in the placebo arm of AFCAPS-TexCAPS; n ¼ 2,802) (Fig. 1D) . Tables 2 and 3 , respectively. Online Tables 4 and 5, respectively, show equivalent analyses using the alternative LDL-C cutoffs of <50, <70, <100, <130, <160, and <190 mg/dl and non-HDL-C cutoffs of <80, <100, <130, <160, <190, and <220 mg/dl.
Online Table 6 shows the risk for hemorrhagic stroke, Very Low LDL-C Levels and CVD Risk of hemorrhagic strokes was low and, therefore, statistical power was limited, the results suggest that the risk for hemorrhagic stroke was somewhat higher among patients achieving very low levels of atherogenic lipoproteins compared with that in those achieving moderately low levels. It is well-known that there is large interindividual variation in the response to statin therapy. However, our results highlight an underappreciated aspect, namely, that some patients achieve a large reduction of atherogenic lipoprotein levels, whereas others respond poorly. Therefore, the current management of dyslipidemia continues to be suboptimal (22) .
DISCUSSION
Multiple patient characteristics, including sex, age, smoking status, body weight, diet, and physical activity have been reported to contribute to variations in statin-induced LDL-C reduction, but the impact of these factors is modest (23) (24) (25) . However, Values are n (%) unless otherwise indicated. *Adjusted for sex, age, smoking status, presence of diabetes mellitus, systolic blood pressure, high-density lipoprotein cholesterol (HDL-C) concentration, and trial. The highest non-HDL-C category was used as the reference category.
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